ATTR-CM is the zebra hiding among the horses. AI may finally be the tool that finds it. Experts Drs Kevin Alexander and Lily Stern explore what's working, what's not, and what comes next.

In the latest Skills Lab, Dr Bishal Gyawali breaks down effect size in oncology, revealing how overpowered trials can turn trivial gains into 'significant' results.

John Mandrola discusses the sham-controlled trial of percutaneous coronary intervention for chronic total occlusions with ORBITA-CTO investigators Sarosh Khan and John Davies.

Drs Kevin Alexander and Joban Vaishnav explore when and how to use genetic testing in ATTR-CM, why distinguishing hereditary from wild-type disease matters, and what this means for patients' families.

Aging may not be permanent. Nir Barzilai explains how human cells reset to zero and why partial rejuvenation could be possible within decades.

Abundant randomized trial data support using nurses instead of physicians in certain healthcare roles, but does that mean we should do it?

Ethicist Art Caplan discusses federal vaccine policy changes in the United States.

Drs Ileana Piña and Ambarish Pandey discuss results from the FOOD-HF study and the concept behind food as medicine.

Advances in glomerular diseases (GDs) from ASN 2025 include 52-week results on pegcetacoplan, data on emerging therapies, and GD outcomes across the lifespan, as reported by Dr Andrew Bomback.

Ethicist Art Caplan discusses a recent case highlighting the need for a deeper understanding of patient motivations when making ethical decisions.